Supplementary Table 2.
Consensus a cross the topic areas
| Topics | Questions | Consensus | No consensus |
|---|---|---|---|
| 1. Biochemical recurrence following radical local definitive therapy | 4, 5, 6, (7 eliminated) | 3 | 0 |
| 2. Non-metastatic castration-resistant prostate cancer (nmCRPC) | 8, 9, 10, 11, 12, 13, 14, 15, 16, 19, 20, 21 | 5 | 7 |
| 3. Metastatic castration-sensitive prostate cancer (mCSPC) | 22, 22b, 23, 24, 25, 26, 27, 28, 29, 30, 31 | 4 | 7 |
| 4. Sequencing of Systemic Treatment | 17, 18, 32, 34, 35, 36, 38, 39, 40, 41, 42 | 10 | 1 |
| 5. Metastatic castration-resistant prostate cancer (mCRPC) | 33, 37, 43, 44, 45 | 3 | 2 |
| 6. Oligometastatic prostate cancer | 46, 47, 48, 49, 50 | 0 | 5 |
| 7. Funding of treatments | 51, 52 | 0 | 2 |
| 8. Referral for care | 60, 61, 62 | 0 | 3 |
| 9. Genetic testing in prostate cancer | 53, 54, 55, 56, 57, 58, 59 | 3 | 4 |
| 10. Imaging in advanced prostate cancer | 63, 64, 65, 66, 67 | 2 | 3 |